



Accredited by
Joint Commission International

Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



A. K. SINGHAL

Vice President
Cum Company Secretary

Ref: IMCL/CS/BM/2018

10th November, 2018

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Sub.: Unaudited Financial Results for the quarter and half year ended 30th September, 2018

Dear Sir,

Enclosed please find a copy of the Unaudited Financial Results for the quarter and half year ended 30th September, 2018, along with a copy of the Limited Review Report by the Auditors.

The Board meeting started at 03:00 pm and ended at 5.15 p.m.

This is for your information and record.

Thanking You,

Sincerely Yours,

A.K.SINGHAL

Encl. as above

S.N.Dhawan & CO LLP

Chartered Accountants

Limited Review Report

To The Board of Directors of
Indraprastha Medical Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter ended September 30, 2018 and the year to-date results for the period April 01, 2018 to September 30, 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, other accounting principles generally accepted in India and SEBI Circular dated 5 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S.N. Dhawan & Co LLP**
Chartered Accountants
Firm Registration No.: 000050N/N500045




Rajeev K Saxena
Partner
Membership No.: 077974
New Delhi, November 10, 2018

Statement of Unaudited Financial Results for the Quarter and Half-year ended 30th September, 2018

S. No.	Particulars	Amount (Rs. in Lacs)					
		Quarter ended			Half year ended		Financial Year ended
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
1	Revenue from operations	20017.35	18937.87	19190.69	38955.22	37695.46	75186.32
2	Other Income	8.01	7.70	9.83	15.71	18.53	159.93
3	Total income	20025.36	18945.57	19200.52	38970.93	37713.99	75346.25
4	Expenses						
	a) Cost of material consumed	3647.67	3572.84	3575.47	7220.51	7218.66	13984.14
	b) Employee benefits expense	5006.13	4770.63	4830.46	9776.75	9454.07	19401.37
	c) Consultation fee paid to Doctors	5036.84	4881.58	5025.57	9918.42	9902.75	19376.42
	d) Finance cost	173.20	178.42	230.27	351.62	442.48	889.94
	e) Depreciation and amortisation expense	755.78	754.52	777.38	1510.30	1536.18	3068.18
	f) Other expenses	4183.36	3762.01	3947.77	7945.37	7617.79	15225.68
	Total expenses	18802.98	17920.00	18386.92	36722.97	36171.93	71945.73
5	Profit before exceptional items and tax	1222.38	1025.57	813.60	2247.96	1542.06	3400.52
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (PBT)	1222.38	1025.57	813.60	2247.96	1542.06	3400.52
8	Tax expense						
	Current tax	558.01	479.80	293.78	1037.81	609.34	1393.07
	Deferred tax	(102.88)	(102.74)	(4.61)	(205.62)	(67.66)	(102.88)
9	Profit for the period after tax (PAT)	767.25	648.51	524.43	1415.77	1000.38	2110.33
10	Other comprehensive income						
	a. (i) Items that will not be reclassified to profit or loss	(17.24)	36.03	24.12	18.79	31.55	37.27
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	6.02	(12.59)	(8.35)	(6.57)	(10.92)	(13.02)
	Total other comprehensive income, Net of tax expenses	(11.22)	23.44	15.77	12.22	20.63	24.25
11	Total comprehensive income for the period	756.03	671.95	540.20	1427.99	1021.01	2134.58
12	Paid-up equity share capital (Face value Rs. 10/- each)	9167.30	9167.30	9167.30	9167.30	9167.30	9167.30
13	Earnings per share Basic and Diluted (Rs.)	0.84	0.71	0.57	1.54	1.09	2.30

Statement of Assets and Liabilities:		Amount (Rs. in Lacs)	
		As at	
		Unaudited 30.09.2018	Audited 31.03.2018
A. ASSETS			
1	Non-current assets		
	(a) Property, Plant and Equipment	28544.89	29277.22
	(b) Intangible Assets	83.99	118.95
	(c) Financial Assets	277.43	276.94
	(d) Other non-current Assets	227.53	335.64
		29133.84	30008.75
2	Current assets		
	(a) Inventories	837.44	912.41
	(b) Financial Assets		
	(i) Trade receivables	8809.30	8745.52
	(ii) Cash and cash equivalents	704.53	251.59
	(iii) Bank Balances other than (ii) above	1951.39	542.55
	(iv) Loans	39.94	39.94
	(v) Others	773.34	659.49
	(c) Current Tax Assets (Net)	569.34	776.48
	(d) Other current assets	1714.71	1683.14
		15399.99	13611.12
	TOTAL OF ASSETS	44533.83	43619.87
B. EQUITY AND LIABILITIES			
1	Equity		
	(a) Equity Share capital	9167.30	9167.30
	(b) Other Equity	13834.25	14064.01
		23001.55	23231.31
	Liabilities		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	1800.00	2100.00
	(ii) Other Financial liabilities	288.05	276.00
	(b) Provisions	883.93	873.04
	(c) Deferred tax liabilities (Net)	2776.92	2975.98
		5748.90	6225.02
3	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	1321.65	3855.75
	(ii) Trade payables	9281.08	7156.49
	(iii) Other financial liabilities	726.79	764.79
	(b) Other current liabilities	3627.59	1649.25
	(c) Provisions	826.27	737.26
		15783.38	14163.54
	TOTAL OF EQUITY AND LIABILITIES	44533.83	43619.87

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 10th November, 2018
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Statutory Auditors have carried out a Limited review of the financial results for the quarter and half-year ending 30th September, 2018.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place: New Delhi
Date : 10th November, 2018



A. Bajpai
Ashok Bajpai
Managing Director